JP2019513748A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019513748A5 JP2019513748A5 JP2018552804A JP2018552804A JP2019513748A5 JP 2019513748 A5 JP2019513748 A5 JP 2019513748A5 JP 2018552804 A JP2018552804 A JP 2018552804A JP 2018552804 A JP2018552804 A JP 2018552804A JP 2019513748 A5 JP2019513748 A5 JP 2019513748A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- fxii
- subject
- pharmaceutical composition
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022084909A JP2022116154A (ja) | 2016-04-06 | 2022-05-25 | アテローム性動脈硬化症の治療方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16164009.9 | 2016-04-06 | ||
| EP16164009 | 2016-04-06 | ||
| PCT/AU2017/050297 WO2017173494A1 (en) | 2016-04-06 | 2017-04-06 | Method of treating atherosclerosis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022084909A Division JP2022116154A (ja) | 2016-04-06 | 2022-05-25 | アテローム性動脈硬化症の治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019513748A JP2019513748A (ja) | 2019-05-30 |
| JP2019513748A5 true JP2019513748A5 (https=) | 2020-05-07 |
| JP7456723B2 JP7456723B2 (ja) | 2024-03-27 |
Family
ID=55759460
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018552804A Active JP7456723B2 (ja) | 2016-04-06 | 2017-04-06 | アテローム性動脈硬化症の治療方法 |
| JP2022084909A Pending JP2022116154A (ja) | 2016-04-06 | 2022-05-25 | アテローム性動脈硬化症の治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022084909A Pending JP2022116154A (ja) | 2016-04-06 | 2022-05-25 | アテローム性動脈硬化症の治療方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11174321B2 (https=) |
| EP (1) | EP3440107A4 (https=) |
| JP (2) | JP7456723B2 (https=) |
| KR (2) | KR20180132831A (https=) |
| CN (1) | CN109071629A (https=) |
| AU (2) | AU2017247004B2 (https=) |
| CA (1) | CA3019851A1 (https=) |
| WO (1) | WO2017173494A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2901225C (en) | 2013-03-08 | 2023-09-19 | Csl Behring Gmbh | Treatment and prevention of remote ischemia-reperfusion injury |
| BR112016029624A2 (pt) | 2014-06-18 | 2017-10-24 | Csl Behring Gmbh | terapia usando um inibidor do fator xii em um distúrbio neurotraumático |
| EP3440107A4 (en) * | 2016-04-06 | 2020-02-19 | CSL Limited | METHOD FOR TREATING ATHEROSCLEROSIS |
| AU2018382222B2 (en) * | 2017-12-15 | 2025-09-04 | Csl Limited | Use of a FXIIa-inhibitor in the treatment of renal fibrosis and/or chronic kidney disease |
| CA3141778A1 (en) * | 2019-06-12 | 2020-12-17 | CSL Innovation Pty Ltd | Soluble complement receptor type 1 variant conjugates and uses thereof |
| AU2020396054A1 (en) * | 2019-12-03 | 2022-07-07 | CSL Innovation Pty Ltd | Use of an anti-Factor XII antibody for the treatment or prevention of hereditary angioedema |
| JP2023531315A (ja) * | 2020-07-03 | 2023-07-21 | シーエスエル・イノベーション・プロプライエタリー・リミテッド | 第ｘｉｉ因子抗原結合タンパク質の高濃度製剤 |
| US20240228585A1 (en) * | 2021-05-03 | 2024-07-11 | President And Fellows Of Harvard College | Fc-fusion protein therapeutic for the treatment of pancreatitis |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
| US4963657A (en) * | 1988-06-09 | 1990-10-16 | Temple University Of The Commonwealth System Of Higher Education | Monoclonal antibodies to the light chain region of human factor XII and methods of preparing and using the same |
| EP0401384B1 (en) | 1988-12-22 | 1996-03-13 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
| US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| DK0575545T3 (da) | 1991-03-15 | 2003-09-15 | Amgen Inc | Pegylering af polypeptider |
| JPH11501506A (ja) | 1994-12-12 | 1999-02-09 | ベス イスラエル デアコネス メディカル センター | キメラ型サイトカインおよびその利用 |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| EP2206720A1 (en) | 2000-04-12 | 2010-07-14 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US20080108560A1 (en) | 2002-03-05 | 2008-05-08 | Eli Lilly And Company | Heterologous G-Csf Fusion Proteins |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| PT1624891E (pt) | 2003-05-06 | 2010-01-05 | Syntonix Pharmaceuticals Inc | Proteínas quiméricas de factor de coagulação-fc destinadas ao tratamento da hemofilia |
| MXPA05013565A (es) | 2003-06-12 | 2006-03-09 | Lilly Co Eli | Proteinas de fusion analogas al glp-1. |
| CN1871252A (zh) | 2003-09-05 | 2006-11-29 | Gtc生物治疗学公司 | 在转基因哺乳动物奶中生产融合蛋白的方法 |
| JP2008504008A (ja) | 2003-12-31 | 2008-02-14 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 改良された薬物動態を有するＦｃ−エリスロポエチン融合タンパク質 |
| US8911726B2 (en) | 2004-09-22 | 2014-12-16 | Kyowa Hakko Kirin Co., Ltd | Stabilized human Igg4 antibodies |
| CA2591786C (en) | 2004-12-23 | 2013-07-16 | Bernhard Nieswandt | Prevention of thrombus formation and/or stabilization |
| GB0607515D0 (en) * | 2006-04-13 | 2006-05-24 | Axis Shield Diagnostics Ltd | Anti-factor xlla therapy |
| EP2526962B1 (en) | 2007-02-12 | 2019-08-14 | CSL Behring GmbH | Therapeutic application of Kazal-type serine protease inhibitors |
| EP2376109B1 (en) | 2008-12-19 | 2019-01-23 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
| LV14606B (lv) * | 2011-05-17 | 2013-01-20 | Tetra, Sia | Jauns XII faktora inhibitors |
| ES3005912T3 (en) | 2011-07-22 | 2025-03-17 | Csl Behring Gmbh | Inhibitory anti-factor xii/xiia monoclonal antibodies and their uses |
| JP5653860B2 (ja) * | 2011-07-28 | 2015-01-14 | 富士フイルム株式会社 | 管壁の硬度測定方法および装置 |
| EP2623110A1 (en) * | 2012-01-31 | 2013-08-07 | CSL Behring GmbH | Factor XII inhibitors for the treatment of neurological inflammatory disorders |
| CA2901225C (en) | 2013-03-08 | 2023-09-19 | Csl Behring Gmbh | Treatment and prevention of remote ischemia-reperfusion injury |
| JP2017501968A (ja) * | 2013-06-28 | 2017-01-19 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | 第ｘｉｉ因子インヒビターおよびｃ１−インヒビターを使用する組合せ療法 |
| BR112016029624A2 (pt) * | 2014-06-18 | 2017-10-24 | Csl Behring Gmbh | terapia usando um inibidor do fator xii em um distúrbio neurotraumático |
| EP3440107A4 (en) * | 2016-04-06 | 2020-02-19 | CSL Limited | METHOD FOR TREATING ATHEROSCLEROSIS |
-
2017
- 2017-04-06 EP EP17778478.2A patent/EP3440107A4/en active Pending
- 2017-04-06 AU AU2017247004A patent/AU2017247004B2/en active Active
- 2017-04-06 CN CN201780022190.9A patent/CN109071629A/zh active Pending
- 2017-04-06 KR KR1020187032136A patent/KR20180132831A/ko not_active Ceased
- 2017-04-06 JP JP2018552804A patent/JP7456723B2/ja active Active
- 2017-04-06 KR KR1020237031602A patent/KR20230136687A/ko not_active Ceased
- 2017-04-06 CA CA3019851A patent/CA3019851A1/en active Pending
- 2017-04-06 US US16/090,861 patent/US11174321B2/en active Active
- 2017-04-06 WO PCT/AU2017/050297 patent/WO2017173494A1/en not_active Ceased
-
2021
- 2021-10-11 US US17/498,112 patent/US20220017638A1/en not_active Abandoned
-
2022
- 2022-05-25 JP JP2022084909A patent/JP2022116154A/ja active Pending
- 2022-10-04 AU AU2022241636A patent/AU2022241636B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019513748A5 (https=) | ||
| ES2935419T3 (es) | Constructos de anticuerpo biespecíficos para PSMA y CD3 que se ligan a células T | |
| IL323633A (en) | Humanized anti-kallikrein-2 antibody | |
| CN104968361B (zh) | 用于治疗或预防疾病的因子1蛋白、因子2蛋白及其抑制剂 | |
| CN117222663A (zh) | 使用结合nkg2d、cd16和肿瘤相关抗原的多特异性结合蛋白治疗癌症的方法 | |
| BR112019022751A2 (pt) | composição farmacêutica compreendendo construtos de anticorpos biespecíficos para armazenamento e administração melhorados | |
| AU2020307471A1 (en) | Dosing regimen and combination therapies for multispecific antibodies targeting B-cell maturation antigen | |
| KR20150080033A (ko) | 골관절염 및 통증의 치료 방법 | |
| JP2013516389A (ja) | カリクレイン阻害剤による粘膜炎治療 | |
| JP2025102888A (ja) | Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法 | |
| CN103958542A (zh) | 经修饰的白蛋白结合结构域及其用于改善药代动力学的用途 | |
| US20150203592A1 (en) | Compositions and methods for treating osteoarthritis | |
| KR20210086671A (ko) | 항-vegf 항체 및 항-조직 인자 항체-약물 접합체의 조합을 사용하여 암을 치료하는 방법 | |
| JP2022522889A (ja) | Ａｌアミロイドーシスを処置する方法 | |
| JP2023138982A (ja) | インターロイキン－１７（ｉｌ－１７）アンタゴニストを使用して腱障害を治療する方法 | |
| KR20220093323A (ko) | HLA-A2/WT1 x CD3 이중특이적 항체 및 레날리도미드를 이용한 암의 치료 | |
| JP2017524675A5 (https=) | ||
| JP2024537284A (ja) | 抗ｎｐｒ１抗体を投与することにより血行動態の変化を引き起こす方法 | |
| US20220119538A1 (en) | Anti-il-36r antibodies for treatment of chronic inflammatory pain | |
| GB2520353A (en) | Antibody polypeptides and uses thereof | |
| MX2010012215A (es) | Uso de una molecula radiomarcada que se une especificamente a la ed-b de la fibronectina en un metodo para el linfoma de hodgkin. | |
| US11952416B2 (en) | Anti-annexin A1 antibodies | |
| US20240228666A1 (en) | Therapeutic methods and uses for antibodies to human masp-3 | |
| JP2019505516A (ja) | インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用してざ瘡を治療する方法 | |
| WO2024031049A2 (en) | Pharmaceutical compositions of fusion proteins and methods of use thereof |